268 related articles for article (PubMed ID: 3122217)
21. Trisomy 8 as the sole chromosomal aberration in myelocytic malignancies: a multicolor and locus-specific fluorescence in situ hybridization study.
Paulsson K; Fioretos T; Strömbeck B; Mauritzson N; Tanke HJ; Johansson B
Cancer Genet Cytogenet; 2003 Jan; 140(1):66-9. PubMed ID: 12550762
[TBL] [Abstract][Full Text] [Related]
22. RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study.
Vogelstein B; Civin CI; Preisinger AC; Krischer JP; Steuber P; Ravindranath Y; Weinstein H; Elfferich P; Bos J
Genes Chromosomes Cancer; 1990 Jul; 2(2):159-62. PubMed ID: 2278970
[TBL] [Abstract][Full Text] [Related]
23. Mutation analysis of the ras gene in myelocytic leukemia by polymerase chain reaction and oligonucleotide probes.
Liu TC; Lin SF; Chen TP; Liu HW; Chang JG
J Formos Med Assoc; 1991 Sep; 90(9):825-30. PubMed ID: 1683380
[TBL] [Abstract][Full Text] [Related]
24. [Activation of ras oncogene in myelodysplastic syndrome and acute myelogenous leukemia].
Hirai H; Hirano N; Yazaki Y
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1090-7. PubMed ID: 2053767
[TBL] [Abstract][Full Text] [Related]
25. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
[TBL] [Abstract][Full Text] [Related]
26. Activation mechanism of the N-ras oncogene in human leukemias detected by synthetic oligonucleotide probes.
Nishida J; Hirai H; Takaku F
Biochem Biophys Res Commun; 1987 Sep; 147(2):870-5. PubMed ID: 3477229
[TBL] [Abstract][Full Text] [Related]
27. The role of ras gene mutations in myeloproliferative disorders.
Liu ET
Clin Lab Med; 1990 Dec; 10(4):797-807. PubMed ID: 2272174
[TBL] [Abstract][Full Text] [Related]
28. [Classification of myeloid leukemias].
Kuriyama K
Nihon Rinsho; 2009 Oct; 67(10):1853-62. PubMed ID: 19860179
[TBL] [Abstract][Full Text] [Related]
29. [Mutations in TET2 in myeloid cancers].
Bernard OA; Delhommeau F; Fontenay M; Vainchenker W
Med Sci (Paris); 2009 Oct; 25(10):785-8. PubMed ID: 19849974
[No Abstract] [Full Text] [Related]
30. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
[TBL] [Abstract][Full Text] [Related]
31. ras gene activation in a minor proportion of the blast population in acute myeloid leukemia.
Toksoz D; Farr CJ; Marshall CJ
Oncogene; 1987; 1(4):409-13. PubMed ID: 3330783
[TBL] [Abstract][Full Text] [Related]
32. Mutation in TET2 in myeloid cancers.
Tefferi A; Lim KH; Levine R
N Engl J Med; 2009 Sep; 361(11):1117; author reply 1117-8. PubMed ID: 19741235
[No Abstract] [Full Text] [Related]
33. Mutations in N-ras predominate in acute myeloid leukemia.
Bos JL; Verlaan-de Vries M; van der Eb AJ; Janssen JW; Delwel R; Löwenberg B; Colly LP
Blood; 1987 Apr; 69(4):1237-41. PubMed ID: 3103719
[TBL] [Abstract][Full Text] [Related]
34. ras mutations in human leukemia and related disorders.
Greenberger JS
Int J Cell Cloning; 1989 Nov; 7(6):343-59. PubMed ID: 2681441
[TBL] [Abstract][Full Text] [Related]
35. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
[TBL] [Abstract][Full Text] [Related]
36. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
37. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Forghieri F; Paolini A; Morselli M; Bigliardi S; Bonacorsi G; Leonardi G; Coluccio V; Maccaferri M; Fantuzzi V; Faglioni L; Colaci E; Soci F; Nasillo V; Messerotti A; Arletti L; Pioli V; Zucchini P; Quadrelli C; Corradini G; Giacobbi F; Vallerini D; Riva G; Barozzi P; Lagreca I; Marasca R; Narni F; Mecucci C; Ottaviani E; Martinelli G; Falini B; Luppi M; Potenza L
Leuk Lymphoma; 2015; 56(11):3222-6. PubMed ID: 25813079
[No Abstract] [Full Text] [Related]
38. Expression of the interleukin 6 gene in acute myeloid leukemia and myelodysplastic syndromes: a report on 49 cases.
Collyn d'Hooghe M; Fenaux P; Lantoine D; Loucheux-Lefebvre M; Kerckaert JP
Nouv Rev Fr Hematol (1978); 1990; 32(3):175-7. PubMed ID: 2216700
[TBL] [Abstract][Full Text] [Related]
39. 12th codon mutation resulting in c-N-ras activation in acute myelogenous leukemia.
Needleman SW; Devine SE; Kraus MH
Leukemia; 1988 Feb; 2(2):91-3. PubMed ID: 3278172
[TBL] [Abstract][Full Text] [Related]
40. Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci.
Bartram CR; Ludwig WD; Hiddemann W; Lyons J; Buschle M; Ritter J; Harbott J; Fröhlich A; Janssen JW
Leukemia; 1989 Apr; 3(4):247-56. PubMed ID: 2564452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
